Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR97276A in pediatric uncomplicated malaria
NCT01445938Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2011
- Primary completion
- Jan 2012
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of albitiazolium bromide in malaria (3 arms), sponsored by Sanofi. Primary endpoint: Parasite Reduction Ratio at 72 hours. Started Oct 2011; status: terminated.
02
Drugs
albitiazolium bromide
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01445938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445938.